You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The effort, called INNO4COV-19, was awarded €6.1 million last month to support the commercialization of new diagnostics.
Color Genomics' kit is designed for the unmonitored self-collection of nasal swab specimens for SARS-CoV-2 testing.
The tests are designed to detect viral RNA in individual respiratory specimens, while BayCare's tests can be used with pooled samples.
The scientists received backing in the form of a €2.4 million EU grant this month and have founded a company, called Biopix-T, to commercialize the platform.
Grassroots efforts are leading the way in a number of commercial and non-commercial screening tests in development.
The point-of-care test is based on technology developed at the Columbia University Fertility Center for preimplantation genetic testing.
The company is also working on a diagnostic COVID-19 test, called LamPore, that will run on its MinIon and GridIon nanopore sequencing platforms
The test does not require thermal cycling and uses a colorimetric readout, making it more amenable to high-throughput automation and rapid scale-up, the company said.
Assays like SwabSeq, Dx-Seq, and LAMP-Seq promise to analyze tens to hundreds of thousands of samples in parallel but might be constrained by sample availability.
A handful of rapid 2019-nCoV assays are in the works which could help triage patients more effectively and avoid unnecessary quarantines.